scholarly journals Preoperative heart failure is not associated with impaired coagulation in paediatric cardiac surgery

2021 ◽  
pp. 1-6
Author(s):  
Fredrik Söderlund ◽  
Håkan Wåhlander ◽  
Emma C. Hansson ◽  
Birgitta S. Romlin

Abstract Objective: The objectives of the present study were to determine whether there was any association between the grade of heart failure, as expressed by preoperative levels of brain natriuretic peptide and Ross score, and the preoperative coagulation status in patients with non-restrictive ventricular shunts and determine whether there were any postoperative disturbances of the coagulation system in these patients, as measured by thromboelastometry and standard laboratory analyses of coagulation. Design: Perioperative coagulation was analysed with laboratory-based coagulation tests and thromboelastometry before, 8 hours after, and 18 hours after cardiac surgery. In addition, brain natriuretic peptide was analysed before and 18 hours after surgery. Patients: 40 children less than 12 months old with non-restrictive congenital ventricular or atrio-ventricular shunts scheduled for elective repair of their heart defects. Results: All coagulation parameters measured were within normal ranges preoperatively. There was a significant correlation between brain natriuretic peptide and plasma fibrinogen concentration preoperatively. There was no statistically significant correlation between brain natriuretic peptide and INTEM-MCF, FIBTEM-MCF, plasma fibrinogen, activated partial thromboplastin time, prothrombin time, or platelet count at any other time point, either preoperatively or postoperatively. Postoperatively, fibrinogen plasma concentration and FIBTEM-MCF decreased significantly at 8 hours, followed by a large increase at 18 hours to higher levels than preoperatively. Conclusions: There was no evidence of children with non-restrictive shunts having coagulation abnormalities before cardiac surgery. Brain natriuretic peptide levels or Ross score did not correlate with coagulation parameters in any clinically significant way.

2013 ◽  
Vol 0 (12) ◽  
pp. 42
Author(s):  
Ю. В. Давыдова ◽  
Л. Г. Воронков ◽  
І. В. Чібісова ◽  
А. Ю. Лиманська ◽  
О. М. Мокрик ◽  
...  

2019 ◽  
Vol 100 (5) ◽  
pp. 823-827
Author(s):  
D S Bublikov ◽  
N V Duruda ◽  
T V Kudeyarova ◽  
E B Klester ◽  
A S Pinaeva ◽  
...  

Aim. To evaluate the efficacy of eplerenone and candesartan in heart failure correction in a patient with Ebstein's anomaly detected in adulthood. Methods. A clinical case of long-term follow-up of a patient with a rare pathology, Ebstein's anomaly detected in adulthood, is described. The data of subjective examination are given. The anomaly was identified during a screening heart ultrasound exam, the patient had no complaints before, and had no history of chronic diseases, including congenital heart defects among family members. Also, the patient underwent routine diagnostic methods general clinical studies, cardiac echocardiography, magnetic resonance imaging of the heart, N-terminal pro-brain natriuretic peptide measurement. In addition, the effect of correcting the signs of heart failure with a combination of candesartan and eplerenone in the complex treatment of heart failure according to echocardiography data and the level of N-terminal pro-brain natriuretic peptide is shown. Results. A decrease in the level of N-terminal pro-brain natriuretic peptide, an increase of the ejection fraction according to echocardiography with the use of eplerenone and candesartan in the complex treatment of heart failure in these patients were demonstrated. Conclusion. Despite the limited data on the use of antagonists of mineralcorticoid receptors and angiotensin receptor blockers among the patients with Ebstein's anomaly, the clinical case presented in the article demonstrates high effectiveness of this combination in treating heart failure in such patients.


Sign in / Sign up

Export Citation Format

Share Document